— Know what they know.
Not Investment Advice

BBIO NASDAQ

BridgeBio Pharma, Inc.
1W: +2.7% 1M: +4.1% 3M: -17.0% YTD: -11.3% 1Y: +27.9% 3Y: +182.3% 5Y: +47.1%
$69.37
+1.22 (+1.79%)
 
Weekly Expected Move ±3.8%
$63 $66 $69 $71 $74
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 58 · $13.6B mcap · 167M float · 1.80% daily turnover · Short 59% of daily vol
Credit Risk of going bust: lower than 52% of companies Debt: 15.5% of company value Bonds: $309.3M held by 77 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.42 (down 98%), BridgeBio Pharma, Inc. would be worth roughly what it owes.
Total debt $2.49B against a stock market value of $13.56B.
Distance to default 5.37 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.51B (short-term plus half of long-term), stock volatility 46.4%; Altman Z'' -14.10. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
48.2 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: 57.9%
Cost Advantage
54
Intangibles
33
Switching Cost
47
Network Effect
82
Scale
34
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. BBIO shows a Weak competitive edge (48.2/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Network Effects. ROIC of 57.9% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$87
Low
$109
Avg Target
$156
High
Based on 11 analysts since Aug 10, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 25Hold: 3Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$109.27
Analysts11
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-10-21 Morgan Stanley — $97 $87 -10 +28.7% $67.62
2026-10-19 Piper Sandler — $115 $120 +5 +80.8% $66.39
2026-10-14 UBS — $72 $92 +20 +41.7% $64.94
2026-10-07 Barclays — $157 $156 -1 +133.0% $66.96
2026-09-01 Mizuho Securities — $96 $110 +14 +43.6% $76.59
2026-08-12 Truist Financial Danielle Brill $102 $107 +5 +27.5% $83.89
2026-08-12 Canaccord Genuity — $104 $106 +2 +26.6% $83.70
2026-08-11 Cantor Fitzgerald Josh Schimmer Initiated $110 — +29.8% $84.72
2026-08-11 Morgan Stanley Sean Laaman $98 $97 -1 +14.6% $84.67
2026-08-11 Wells Fargo Derek Archila $88 $102 +14 +20.5% $84.67
2026-08-11 Piper Sandler — $98 $115 +17 +35.8% $84.67
2026-07-13 H.C. Wainwright — $110 $120 +10 +39.7% $85.89
2026-06-16 Mizuho Securities Salim Syed $53 $96 +43 +41.2% $68.00
2026-06-03 Canaccord Genuity — Initiated $104 — +62.8% $63.88
2026-05-28 Morgan Stanley — $96 $98 +2 +49.4% $65.59
2026-05-11 H.C. Wainwright — $100 $110 +10 +63.2% $67.39
2026-05-08 Evercore ISI — $50 $130 +80 +95.4% $66.53
2026-05-08 Bernstein — $94 $114 +20 +69.0% $67.45
2026-04-29 Truist Financial Danielle Brill $95 $102 +7 +45.5% $70.08
2026-04-08 RBC Capital Luca Issi Initiated $100 — +34.9% $74.14
2026-03-12 Leerink Partners Mani Foroohar $86 $98 +12 +42.5% $68.77
2026-02-25 Truist Financial Danielle Brill $86 $95 +9 +44.5% $65.75
2026-02-17 H.C. Wainwright Raghuram Selvaraju $90 $100 +10 +32.9% $75.25
2026-02-13 Tudor Pickering William Pickering Initiated $100 — +30.6% $76.59
2026-02-13 Oppenheimer Trevor Allred $81 $83 +2 +8.9% $76.22
2026-02-12 Jefferies Andrew Tsai Initiated $100 — +31.5% $76.06
2026-02-12 Raymond James Martin Auster $69 $89 +20 +14.5% $77.74
2026-01-27 Barclays — Initiated $157 — +101.6% $77.87
2026-01-20 Wells Fargo Tiago Fauth $58 $88 +30 +15.4% $76.26
2026-01-08 Truist Financial — $80 $86 +6 +15.8% $74.27
2026-01-06 Morgan Stanley — Initiated $96 — +30.8% $73.42
2025-12-15 Leerink Partners — $68 $86 +18 +15.3% $74.59
2025-12-11 Bernstein — Initiated $94 — +29.3% $72.70
2025-10-30 Truist Financial — Initiated $80 — +25.2% $63.88
2025-10-30 Oppenheimer — Initiated $81 — +25.8% $64.39
2025-10-30 Piper Sandler — $46 $98 +52 +47.1% $66.62
2025-10-30 Goldman Sachs Paul Choi $50 $100 +50 +50.1% $66.62
2025-10-29 H.C. Wainwright — $80 $90 +10 +36.9% $65.73
2025-10-28 H.C. Wainwright — $70 $80 +10 +26.3% $63.33
2025-10-27 Raymond James — $46 $69 +23 +9.2% $63.20
2025-10-27 Leerink Partners Mani Foroohar $46 $68 +22 +6.9% $63.61
2025-08-29 H.C. Wainwright Raghuram Selvaraju $43 $70 +27 +35.9% $51.51
2025-04-30 UBS Eliana Merle $47 $72 +25 +87.7% $38.36
2024-10-24 Citigroup David Lebowitz Initiated $45 — +86.2% $24.17
2024-10-17 Leerink Partners Mani Foroohar Initiated $46 — +74.6% $26.34
2024-09-11 Piper Sandler Biren Amin Initiated $46 — +59.8% $28.78
2024-09-03 Mizuho Securities Salim Syed Initiated $53 — +77.1% $29.92
2024-06-24 Raymond James Danielle Brill $17 $46 +29 +103.1% $22.64
2024-06-05 BMO Capital Kostas Biliouris Initiated $37 — +37.4% $26.93
2024-06-05 Wells Fargo Tiago Fauth Initiated $58 — +113.8% $27.13

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
Oct 27, 2026
DCF
1
ROE
5
ROA
1
D/E
1
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. BBIO receives an overall rating of C. Strongest factors: ROE (5/5). Areas of concern: DCF (1/5), ROA (1/5), D/E (1/5), P/E (1/5), P/B (1/5).

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 30 Grade D
Profitability
20
Balance Sheet
30
Earnings Quality
18
Growth
77
Value
23
Momentum
71
Safety
0
Cash Flow
30
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. BBIO scores highest in Growth (77/100) and lowest in Safety (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
-3.29
Distress Zone
Piotroski F-Score
4/9
✗ ✗ ✓ ✓ ✓ ✗ ✗ ✗ ✓
Beneish M-Score
-2.01
Unlikely Manipulator
Ohlson O-Score
8.54
Bankruptcy prob: 100.0%
High Risk
Credit Rating
B-
Score: 20.0/100
Trend: Stable
Earnings Quality
—
OCF/NI: 0.62x
Accruals: -22.8%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. BBIO scores -3.29, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. BBIO scores 4/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. BBIO's score of -2.01 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. BBIO's implied 100.0% bankruptcy probability signals significant financial distress. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. BBIO receives an estimated rating of B- (score: 20.0/100), with a stable trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-19.38x
PEG
-1.50x
P/S
19.02x
P/B
-5.40x
P/FCF
-33.15x
P/OCF
—
EV/EBITDA
-26.91x
EV/Revenue
22.94x
EV/EBIT
-26.54x
EV/FCF
-37.18x
Earnings Yield
-4.77%
FCF Yield
-3.02%
Shareholder Yield
1.47%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. BBIO currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.986
NI / EBT
×
Interest Burden
1.146
EBT / EBIT
×
EBIT Margin
-0.864
EBIT / Rev
×
Asset Turnover
0.621
Rev / Assets
×
Equity Multiplier
-0.534
Assets / Equity
=
ROE
32.4%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. BBIO's ROE of 32.4% is driven by Asset Turnover (0.621), indicating efficient use of assets to generate revenue. A tax burden ratio of 0.99 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$69.37
Median 1Y
$52.85
5th Pctile
$12.46
95th Pctile
$224.92
Ann. Volatility
88.0%
Analyst Target
$109.27
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Neil Kumar, Ph.D.
Chief Executive Officer
$1,044,000 $10,606,275 $14,944,585
Thomas Trimarchi, Ph.D.
President and Chief Financial Officer
$675,589 $4,602,488 $5,832,369
Brian Stephenson, Ph.D.,
CFA Former Chief Financial Officer
$156,431 $— $684,661

CEO Pay Ratio

22:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $14,944,585
Avg Employee Cost (SGA/emp): $665,635
Employees: 834

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
834
+15.0% YoY
Revenue / Employee
$602,012
Rev: $502,078,000
Profit / Employee
$-874,468
NI: $-729,306,000
SGA / Employee
$665,635
Avg labor cost proxy
R&D / Employee
$572,585
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE 1.8% 1.4% 83.0% 68.4% 52.2% 45.3% 37.5% 48.0% 52.2% 49.3% 47.3% 37.0% 36.0% 38.0% 49.5% 53.9% 50.4% 41.2% 37.1% 32.4% 32.36%
ROA -68.2% -65.5% -62.5% -52.4% -65.0% -58.8% -59.1% -83.9% -88.5% -1.1% -73.0% -69.9% -66.5% -73.1% -77.2% -82.8% -95.9% -78.6% -64.5% -60.6% -60.61%
ROIC -7.6% -23.9% -29.4% 15.3% 29.6% 136.0% 27.0% 34.4% 28.0% 9.7% -2.4% -8.2% -1.8% 1.1% 1.7% -3.9% 67.0% -7.0% -2.6% 57.9% 57.89%
ROCE -76.8% -61.5% -78.8% -62.5% -69.0% -80.6% -65.4% -1.3% -98.8% -1.4% -65.3% -56.7% -67.8% -57.9% -76.4% -71.8% -87.3% -97.4% -1.1% -1.9% -1.89%
Gross Margin 38.0% 88.0% 20.4% 99.1% -1.2% 65.4% 64.3% 63.5% 85.4% 65.7% 99.7% 72.4% 78.1% 64.6% 97.7% 96.7% 94.6% 90.0% 94.6% 93.8% 93.83%
Operating Margin -63.8% -12.9% -102.5% -1.1% -382.0% -69.1% -69.1% -89.0% -38.5% -101.7% 0.2% -81.0% -70.2% -38.4% -89.5% -1.2% -1.2% -1.2% -54.5% -43.9% -43.94%
Net Margin -66.5% -11.4% -115.9% -13.4% -406.3% -73.6% -76.8% -96.2% -43.3% -96.4% -16.7% -33.9% -59.3% -45.1% -1.4% -1.6% -1.5% -1.3% -84.3% -62.5% -62.47%
EBITDA Margin -63.9% -10.5% -105.7% 26.2% -351.3% -63.6% -66.3% -84.4% -38.5% -85.1% -5.3% -23.5% -51.1% -40.0% -1.1% -1.3% -1.4% -1.2% -57.9% -58.1% -58.09%
FCF Margin -8.9% -7.8% -7.8% -5.5% -5.3% -5.5% -5.3% -86.0% -52.8% -56.9% -2.8% -1.9% -2.1% -2.4% -4.0% -2.8% -1.7% -91.1% -78.3% -61.7% -61.69%
OCF Margin -8.1% -7.1% -7.2% -4.9% -5.2% -5.4% -5.2% -85.7% -52.6% -56.7% -2.8% -1.9% -2.1% -2.3% -3.9% -2.8% -1.7% -88.8% -76.5% -60.9% -60.92%
ROA 3Y Avg snapshot only -62.07%
ROIC Economic snapshot only 12.03%
Cash ROA snapshot only -35.68%
NOPAT Margin snapshot only -60.21%
Pretax Margin snapshot only -99.03%
R&D / Revenue snapshot only 74.46%
SGA / Revenue snapshot only 93.93%
SBC / Revenue snapshot only 15.70%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -12.84 -4.31 -2.48 -2.61 -3.00 -2.37 -5.96 -4.82 -7.03 -10.95 -10.27 -10.47 -10.94 -9.70 -9.84 -10.60 -12.41 -20.69 -19.93 -20.94 -19.377
P/S Ratio 120.70 34.76 20.87 14.69 16.59 14.66 32.54 486.56 456.77 757.07 25.28 21.68 22.04 23.43 51.59 34.89 27.97 30.05 24.94 20.45 19.018
P/B Ratio -9.25 -2.78 -1.42 -1.30 -1.29 -0.91 -2.06 -2.03 -3.57 -5.20 -5.26 -4.35 -3.90 -3.54 -3.99 -4.60 -5.12 -7.27 -6.38 -5.80 -5.400
P/FCF -13.53 -4.44 -2.67 -2.69 -3.14 -2.67 -6.19 -5.66 -8.65 -13.31 -9.12 -11.32 -10.52 -9.81 -12.90 -12.33 -16.63 -32.97 -31.85 -33.15 -33.150
P/OCF — — — — — — — — — — — — — — — — — — — — —
EV/EBITDA -14.70 -6.21 -4.60 -5.23 -6.26 -6.01 -11.03 -8.27 -10.26 -14.76 -14.78 -16.01 -17.88 -14.30 -14.30 -15.77 -16.40 -27.68 -27.77 -26.91 -26.914
EV/Revenue 134.74 47.52 35.76 25.68 29.26 30.78 48.12 724.41 583.18 897.34 30.81 26.90 28.76 28.15 61.93 43.03 31.40 34.31 29.16 22.94 22.937
EV/EBIT -14.57 -6.14 -4.54 -5.17 -6.17 -5.91 -10.82 -8.16 -10.14 -14.60 -14.58 -15.74 -17.57 -14.11 -14.15 -15.63 -16.27 -27.28 -27.37 -26.54 -26.537
EV/FCF -15.10 -6.07 -4.57 -4.70 -5.54 -5.61 -9.16 -8.42 -11.04 -15.78 -11.12 -14.04 -13.72 -11.80 -15.49 -15.20 -18.66 -37.65 -37.24 -37.18 -37.182
Earnings Yield -7.8% -23.2% -40.2% -38.2% -33.4% -42.3% -16.8% -20.8% -14.2% -9.1% -9.7% -9.6% -9.1% -10.3% -10.2% -9.4% -8.1% -4.8% -5.0% -4.8% -4.77%
FCF Yield -7.4% -22.5% -37.5% -37.2% -31.8% -37.4% -16.1% -17.7% -11.6% -7.5% -11.0% -8.8% -9.5% -10.2% -7.8% -8.1% -6.0% -3.0% -3.1% -3.0% -3.02%
EV/Gross Profit snapshot only 24.572
Shareholder Yield snapshot only 1.47%
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 6.68 6.58 6.92 5.46 5.39 4.52 5.72 3.93 5.54 3.32 5.54 4.59 3.19 4.67 4.57 5.19 3.88 2.62 1.44 1.23 1.227
Quick Ratio 6.68 6.58 6.92 5.46 5.39 4.52 5.72 3.93 5.54 3.32 5.54 4.59 3.19 4.67 4.54 5.08 3.76 2.52 1.40 1.17 1.168
Debt/Equity -1.88 -1.98 -1.66 -1.67 -1.51 -1.37 -1.41 -1.27 -1.44 -1.28 -1.65 -1.58 -1.41 -1.18 -1.13 -1.50 -0.96 -1.31 -1.49 -0.99 -0.991
Net Debt/Equity — — — — — — — — — — — — — — — — — — — — —
Debt/Assets 1.79 1.70 2.12 1.99 2.35 2.77 2.76 3.44 2.65 3.18 2.04 2.18 2.60 1.88 2.11 2.48 1.86 2.92 2.47 2.05 2.049
Debt/EBITDA -2.68 -3.23 -3.13 -3.85 -4.14 -4.34 -5.10 -3.49 -3.24 -3.08 -3.79 -4.70 -4.94 -3.96 -3.37 -4.16 -2.75 -4.38 -5.56 -4.10 -4.104
Net Debt/EBITDA -1.53 -1.67 -1.91 -2.24 -2.71 -3.15 -3.57 -2.72 -2.22 -2.31 -2.65 -3.10 -4.18 -2.40 -2.39 -2.98 -1.79 -3.44 -4.02 -2.92 -2.919
Interest Coverage -12.36 -11.54 -9.75 -6.74 -5.57 -5.03 -4.31 -6.25 -6.70 -7.04 -5.46 -4.31 -3.97 -4.46 -4.73 -4.89 -5.63 -6.10 -5.41 -6.86 -6.861
Equity Multiplier -1.05 -1.16 -0.78 -0.84 -0.64 -0.50 -0.51 -0.37 -0.54 -0.40 -0.81 -0.73 -0.54 -0.63 -0.53 -0.60 -0.52 -0.45 -0.60 -0.48 -0.484
Cash Ratio snapshot only 0.809
Debt Service Coverage snapshot only -6.765
Cash to Debt snapshot only 0.289
FCF to Debt snapshot only -0.176
Defensive Interval snapshot only 294.2 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.07 0.08 0.07 0.09 0.12 0.09 0.11 0.01 0.01 0.02 0.30 0.34 0.33 0.30 0.15 0.25 0.43 0.54 0.51 0.62 0.621
Inventory Turnover — — — — — — — — — — — — — — 2.99 0.98 1.22 2.11 1.95 1.33 1.334
Receivables Turnover 7.04 7.06 12.40 5.50 5.41 4.22 7.15 0.36 0.63 0.99 1.78 47.26 77.11 68.56 0.73 6.08 6.05 6.97 3.62 4.30 4.304
Payables Turnover 0.14 0.30 0.44 0.32 0.39 0.29 0.39 0.42 0.34 0.22 0.54 0.22 0.27 0.38 0.37 0.41 0.93 1.23 1.27 1.78 1.779
DSO 52 52 29 66 67 87 51 1011 576 369 206 8 5 5 502 60 60 52 101 85 84.8 days
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 122 372 300 173 187 274 273.5 days
DPO 2554 1221 836 1124 934 1246 946 877 1070 1657 671 1679 1361 954 994 900 392 296 286 205 205.1 days
Cash Conversion Cycle -2502 -1169 -807 -1058 -866 -1159 -895 134 -494 -1288 -466 -1671 -1356 -949 -370 -468 -32 -71 1 153 153.2 days
Fixed Asset Turnover snapshot only 31.969
Operating Cycle snapshot only 358.3 days
Cash Velocity snapshot only 0.990
Capital Intensity snapshot only 1.707
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 1.6% 7.5% 7.1% 44.5% 55.7% 11.4% 9.6% -93.7% -89.4% -88.0% 1.8% 37.6% 22.1% 22.9% -41.7% 7.6% 62.5% 1.3% 3.6% 2.0% 2.02%
Net Income -33.1% -25.4% -14.6% -2.8% 8.3% 14.5% 28.7% -12.5% -24.8% -33.7% -26.7% 20.8% 28.4% 16.7% -24.1% -71.1% -81.6% -36.1% -8.7% 10.3% 10.33%
EPS -7.2% -2.7% -8.9% -2.9% 9.1% 16.8% 31.8% -2.8% -13.1% -14.4% -8.2% 32.2% 37.9% 23.3% -16.6% -68.5% -79.7% -30.7% -6.1% 12.7% 12.74%
FCF -31.4% -34.1% -17.7% -3.8% 7.9% 22.0% 26.4% 1.5% -6.3% -24.2% -48.2% 14.0% 8.3% -0.1% 15.9% -59.0% -30.4% 13.6% 10.9% 34.1% 34.10%
EBITDA -23.3% -14.6% -4.7% 9.4% 20.6% 25.5% 38.5% -11.7% -29.4% -42.3% -34.3% 25.9% 34.6% 22.7% -21.1% -74.8% -93.4% -42.5% -10.3% 5.6% 5.58%
Op. Income -26.5% -21.5% -8.0% -11.8% -1.9% 11.2% 20.3% 6.7% -1.9% -18.6% -3.5% 3.8% 2.7% 2.4% -45.1% -28.6% -12.0% 4.0% 18.2% 17.2% 17.21%
OCF Growth snapshot only 33.77%
Asset Growth snapshot only 12.69%
Debt Growth snapshot only -6.85%
Shares Change snapshot only 2.77%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y — — — — 49.1% 24.2% 24.2% -48.1% -24.5% 4.1% 1.9% 51.7% 56.4% 47.1% 21.6% 37.5% 58.6% 86.3% 95.4% 4.0% 4.01%
Revenue 5Y — — — — — — — — — — — — 52.1% 40.5% 25.7% 42.2% 74.4% 1.3% 1.3% 62.6% 62.60%
EPS 3Y — — — — — — — — — — — — — — — — — — — — —
EPS 5Y — — — — — — — — — — — — — — — — — — — — —
Net Income 3Y — — — — — — — — — — — — — — — — — — — — —
Net Income 5Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 3Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 5Y — — — — — — — — — — — — — — — — — — — — —
Gross Profit 3Y — — — — 51.5% 24.9% 25.4% -56.9% -31.9% -6.0% 1.9% 51.3% 57.2% 48.5% 22.3% 38.4% 59.0% 85.5% 93.5% 5.0% 5.03%
Gross Profit 5Y — — — — — — — — — — — — 54.8% 41.8% 26.1% 42.9% 72.9% 1.2% 1.3% 60.4% 60.43%
Op. Income 3Y — — — — — — — — — — — — — — — — — — — — —
Op. Income 5Y — — — — — — — — — — — — — — — — — — — — —
FCF 3Y — — — — — — — — — — — — — — — — — — — — —
FCF 5Y — — — — — — — — — — — — — — — — — — — — —
OCF 3Y — — — — — — — — — — — — — — — — — — — — —
OCF 5Y — — — — — — — — — — — — — — — — — — — — —
Assets 3Y — — — 38.4% 4.4% -0.5% -14.2% -17.8% -6.0% -8.1% -8.1% -9.8% -5.2% -3.2% 2.7% 7.8% 11.1% 14.5% 29.9% 34.2% 34.20%
Assets 5Y — — — — — — — — — — — 19.5% 0.8% 7.8% -2.3% 3.6% 4.9% 5.9% 4.6% 2.4% 2.39%
Equity 3Y — — — — — — — — — — — — — — — — — — — — —
Book Value 3Y — — — — — — — — — — — — — — — — — — — — —
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability 0.63 0.22 0.24 0.98 0.85 0.50 0.50 0.08 0.00 0.00 0.86 0.45 0.37 0.30 0.52 0.55 0.65 0.65 0.64 0.64 0.641
Earnings Stability 0.96 0.96 0.92 0.86 0.74 0.63 0.22 0.84 0.80 0.75 0.28 0.59 0.47 0.59 0.51 0.60 0.45 0.58 0.45 0.51 0.507
Margin Stability 0.95 0.97 0.96 0.97 0.96 0.97 0.97 0.75 0.87 0.87 0.97 0.74 0.89 0.89 0.98 0.78 0.88 0.88 0.97 0.78 0.778
Rev. Growth Consistency 0.50 0.50 0.50 1.00 1.00 1.00 1.00 0.00 0.00 0.00 1.00 0.50 0.50 0.50 0.00 1.00 1.00 1.00 0.50 1.00 1.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.00 0.00 0.00 0.00 0.00 0.50 0.500
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.87 0.90 0.94 0.99 0.97 0.94 0.89 0.95 0.90 0.87 0.89 0.92 0.89 0.93 0.90 0.50 0.50 0.86 0.97 0.96 0.959
Earnings Smoothness — — — — — — — — — — — — — — — — — — — — —
ROE Trend — — — — — — — — — — — — — — — — — — — — —
Gross Margin Trend 0.02 -0.01 -0.03 -0.02 -0.04 -0.02 -0.00 -0.44 -0.23 -0.22 0.04 0.25 0.15 0.14 -0.02 0.20 0.10 0.08 -0.03 -0.04 -0.042
FCF Margin Trend 2.12 19.28 22.77 2.10 7.99 23.12 25.72 -79.47 -45.70 -50.21 3.77 43.82 26.95 28.79 0.01 41.13 25.77 28.72 2.60 1.76 1.756
Sustainable Growth Rate — — — — — — — — — — — — — — — — — — — — —
Internal Growth Rate — — — — — — — — — — — — — — — — — — — — —
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.86 0.89 0.85 0.88 0.94 0.87 0.95 0.85 0.81 0.82 1.12 0.91 1.03 0.97 0.75 0.84 0.73 0.61 0.61 0.62 0.624
FCF/OCF 1.10 1.10 1.09 1.11 1.02 1.02 1.01 1.00 1.00 1.00 1.00 1.01 1.01 1.02 1.02 1.02 1.02 1.03 1.02 1.01 1.013
FCF/Net Income snapshot only 0.632
CapEx/Revenue 84.0% 69.2% 66.4% 53.8% 9.1% 8.1% 7.0% 35.2% 17.7% 14.0% 1.3% 2.2% 2.8% 4.0% 7.1% 4.9% 2.9% 2.3% 1.8% 0.8% 0.77%
CapEx/Depreciation snapshot only 0.639
Accruals Ratio -0.10 -0.08 -0.09 -0.06 -0.04 -0.08 -0.03 -0.13 -0.17 -0.20 0.09 -0.06 0.02 -0.02 -0.19 -0.13 -0.26 -0.31 -0.25 -0.23 -0.228
Sloan Accruals snapshot only -0.472
Cash Flow Adequacy snapshot only -78.762
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — — — — — — — — — — — — — —
FCF Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Total Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Div. Increase Streak — — — — — — — — — — — — — — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 3.0% 8.4% 10.4% 11.0% 0.2% 0.1% 0.1% 0.1% 0.1% 0.1% 0.2% 0.2% 0.2% 0.1% 0.8% 0.7% 0.5% 0.3% 0.6% 1.5% 1.47%
Net Buyback Yield 2.9% 8.3% 10.1% 11.0% 0.2% 0.1% -5.6% -5.1% -10.3% -6.3% -11.1% -12.9% -6.4% -5.9% 0.8% 0.7% 0.5% 0.2% 0.2% 1.1% 1.10%
Total Shareholder Return 2.9% 8.3% 10.1% 11.0% 0.2% 0.1% -5.6% -5.1% -10.3% -6.3% -11.1% -12.9% -6.4% -5.9% 0.8% 0.7% 0.5% 0.2% 0.2% 1.1% 1.10%
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 0.94 0.96 0.97 0.98 0.99 0.99 1.00 0.98 0.98 0.98 0.98 0.98 0.98 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.986
Interest Burden (EBT/EBIT) 1.08 1.09 1.10 1.15 1.18 1.20 1.23 1.16 1.15 1.14 1.18 1.23 1.25 1.22 1.21 1.20 1.18 1.16 1.18 1.15 1.146
EBIT Margin -9.25 -7.74 -7.88 -4.97 -4.75 -5.21 -4.45 -88.75 -57.54 -61.48 -2.11 -1.71 -1.64 -2.00 -4.38 -2.75 -1.93 -1.26 -1.07 -0.86 -0.864
Asset Turnover 0.07 0.08 0.07 0.09 0.12 0.09 0.11 0.01 0.01 0.02 0.30 0.34 0.33 0.30 0.15 0.25 0.43 0.54 0.51 0.62 0.621
Equity Multiplier -2.71 -2.11 -1.33 -1.30 -0.80 -0.77 -0.63 -0.57 -0.59 -0.45 -0.65 -0.53 -0.54 -0.52 -0.64 -0.65 -0.53 -0.52 -0.58 -0.53 -0.534
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-3.65 $-3.87 $-4.08 $-3.47 $-3.32 $-3.22 $-2.78 $-3.57 $-3.75 $-3.69 $-3.01 $-2.42 $-2.33 $-2.83 $-3.51 $-4.08 $-4.18 $-3.70 $-3.73 $-3.56 $-3.56
Book Value/Share $-5.07 $-5.99 $-7.14 $-6.99 $-7.70 $-8.40 $-8.03 $-8.48 $-7.39 $-7.76 $-5.87 $-5.83 $-6.52 $-7.75 $-8.67 $-9.38 $-10.15 $-10.53 $-11.65 $-12.85 $-12.80
Tangible Book/Share $-5.38 $-6.30 $-7.34 $-7.20 $-7.89 $-8.59 $-8.21 $-8.66 $-7.56 $-7.91 $-6.02 $-5.96 $-6.65 $-7.88 $-8.82 $-9.54 $-10.30 $-10.67 $-11.79 $-12.98 $-12.98
Revenue/Share $0.39 $0.48 $0.49 $0.62 $0.60 $0.52 $0.51 $0.04 $0.06 $0.05 $1.22 $1.17 $1.16 $1.17 $0.67 $1.24 $1.86 $2.55 $2.98 $3.64 $3.64
FCF/Share $-3.46 $-3.76 $-3.80 $-3.38 $-3.16 $-2.85 $-2.68 $-3.04 $-3.05 $-3.03 $-3.39 $-2.24 $-2.42 $-2.80 $-2.68 $-3.50 $-3.12 $-2.32 $-2.33 $-2.25 $-2.25
OCF/Share $-3.14 $-3.43 $-3.48 $-3.04 $-3.11 $-2.81 $-2.64 $-3.03 $-3.04 $-3.02 $-3.37 $-2.21 $-2.39 $-2.75 $-2.63 $-3.44 $-3.07 $-2.26 $-2.28 $-2.22 $-2.22
Cash/Share $4.09 $5.76 $4.60 $4.88 $4.00 $3.16 $3.39 $2.39 $3.33 $2.49 $2.91 $3.13 $1.41 $3.60 $2.84 $3.98 $3.39 $2.98 $4.83 $3.68 $3.68
EBITDA/Share $-3.56 $-3.67 $-3.78 $-3.03 $-2.80 $-2.66 $-2.22 $-3.10 $-3.28 $-3.24 $-2.55 $-1.96 $-1.86 $-2.31 $-2.90 $-3.38 $-3.55 $-3.16 $-3.13 $-3.10 $-3.10
Debt/Share $9.54 $11.88 $11.84 $11.67 $11.60 $11.54 $11.33 $10.80 $10.62 $9.97 $9.67 $9.22 $9.18 $9.14 $9.77 $14.05 $9.76 $13.83 $17.38 $12.74 $12.74
Net Debt/Share $5.45 $6.12 $7.24 $6.79 $7.60 $8.38 $7.94 $8.41 $7.30 $7.48 $6.77 $6.09 $7.76 $5.54 $6.93 $10.08 $6.37 $10.86 $12.55 $9.06 $9.06
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — -3.294
Altman Z-Prime snapshot only -9.279
Piotroski F-Score 2 2 2 3 3 2 4 1 3 2 3 6 3 5 1 3 5 3 3 4 4
Beneish M-Score 1.03 91.40 6.42 -3.25 13.34 0.32 -3.07 3.23 4.49 -4.44 99.32 -2.82 -2.37 0.09 -3.14 42.78 39.17 18.68 -2.78 -2.01 -2.008
Ohlson O-Score snapshot only 8.538
Net-Net WC snapshot only $-13.43
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only B-
Credit Score 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.000
Credit Grade snapshot only 16
Credit Trend snapshot only 0.000
Implied Spread (bps) snapshot only 900.000
Industry Credit Rank snapshot only 10
Sector Credit Rank snapshot only 11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms